CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5) Nocturnal thoracic volume overload and post-discharge outcomes in patients hospitalized for acute heart failure Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure Association of Cardiovascular Disease With Respiratory Disease Dapagliflozin for treating chronic heart failure with reduced ejection fraction AIM2-driven inflammasome activation in heart failure A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: rationale, design, and baseline patient characteristics.

Original Research2021 Apr 6.

JOURNAL:Ann Intern Med. Article Link

In acute HF and iron deficiency, IV ferric carboxymaltose reduced HF hospitalizations, but not CV death, at 1 y

EM DeFilippis, HGC Van Spall. Keywords: anemia, iron-deficiency; ferric compounds; HF; maltose

LINK

Please click on "Article Link" to get access to this article.